IPP-2 TRZ

IPP-2 TRZ 10mg — Dual GIP/GLP-1 Receptor Agonist Research Peptide

IPP-2 TRZ is a synthetic 39-amino-acid peptide classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Its structure incorporates aminoisobutyric acid (Aib) substitutions and a C20 fatty-diacid moiety that supports an extended plasma half-life, making it a valuable tool compound for investigating incretin-hormone receptor biology and metabolic signaling in preclinical research models. Each vial contains 10mg of lyophilized peptide at ≥99% purity, verified by HPLC and mass spectrometry.

Mechanism of Action

IPP-2 TRZ functions as a single-molecule dual agonist at two distinct incretin receptors: the GIP receptor and the GLP-1 receptor. Both are class B G-protein-coupled receptors (GPCRs) that, upon activation, stimulate adenylate cyclase and elevate intracellular cyclic AMP (cAMP), initiating downstream signaling cascades relevant to pancreatic beta-cell physiology and metabolic regulation (Frías et al., 2021).

GIP Receptor Engagement

IPP-2 TRZ exhibits high affinity for the GIP receptor, approximating that of native GIP. In published research, GIP-receptor activation is studied for its role in glucose-dependent insulin secretion and adipocyte metabolism. The molecule's balanced engagement of the GIP pathway distinguishes it from GLP-1 monoagonists in comparative receptor-pharmacology studies.

GLP-1 Receptor Engagement

At the GLP-1 receptor, IPP-2 TRZ behaves as a biased agonist, with research literature describing a signaling profile that favors cAMP generation over beta-arrestin recruitment. This biased-agonism characteristic is an active area of receptor-pharmacology investigation into how ligand structure influences downstream signaling outcomes.

Extended Half-Life Design

The C20 fatty-diacid moiety promotes reversible albumin binding, and the Aib substitutions confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation. Together these structural features underpin the extended half-life that enables once-weekly dosing schedules used in published research protocols.

Research Applications

IPP-2 TRZ 10mg provides researchers a well-characterized dual-incretin tool compound across several investigational domains supported by the published literature.

Incretin Pathway and Pancreatic Beta-Cell Research

Researchers use IPP-2 TRZ to study glucose-dependent insulinotropic signaling, beta-cell responsiveness, and the interplay between the GIP and GLP-1 axes in cell-culture and animal models. The dual-agonist profile allows investigators to dissect the relative contributions of each incretin pathway to insulin secretion and glucose homeostasis.

Energy Homeostasis and Metabolic Signaling

The compound is employed in research into central and peripheral pathways governing energy balance, adipose-tissue metabolism, and lipid handling. Its distinct receptor-engagement profile makes it a reference ligand for comparative metabolic-signaling studies.

Comparative Receptor Pharmacology

IPP-2 TRZ is widely used as a comparator against GLP-1 monoagonists such as IPP-1 SM to characterize how dual-receptor engagement alters signaling magnitude, receptor internalization, and cellular response in vitro.

Comparison with GLP-1 Monoagonists in Published Literature

In the head-to-head SURPASS-2 trial, IPP-2 TRZ was compared with the GLP-1 monoagonist IPP-1 SM in published clinical research, providing a widely cited reference dataset for comparative incretin pharmacology (Frías et al., NEJM 2021). For researchers, this comparison anchors investigations into whether concurrent GIP-receptor engagement produces measurable differences in receptor signaling and metabolic endpoints relative to GLP-1 activation alone.

Published Research Studies

1. Frías JP, et al. (2021) – New England Journal of Medicine
The SURPASS-2 study compared IPP-2 TRZ with IPP-1 SM, establishing a foundational comparative dataset for dual-incretin versus GLP-1 monoagonist pharmacology (PMID: 34370970).

2. Jastreboff AM, et al. (2022) – New England Journal of Medicine
The SURMOUNT-1 study characterized IPP-2 TRZ's metabolic effects and dose-response profile, forming a key reference for research into incretin-based energy-homeostasis mechanisms (PMID: 35658024).

3. Coskun T, et al. (2018) – Molecular Metabolism
This preclinical characterization described IPP-2 TRZ's dual receptor-binding profile and biased GLP-1 signaling, providing the pharmacological foundation for subsequent research (PMID: 30473097).

Reconstitution and Handling in Research

The following summarizes standard laboratory handling for lyophilized research peptides. IPP-2 TRZ 10mg is intended for research use only and is not for human consumption.

Reconstitute the lyophilized powder by adding bacteriostatic or sterile water down the inside wall of the vial using a sterile syringe. Gently swirl to dissolve—do not shake, as agitation can shear peptide structure. The solvent volume selected determines the working concentration for a given research protocol. For step-by-step technique and dilution calculations, see our peptide reconstitution guide and pair with bacteriostatic water.

Storage and Handling

Lyophilized (unreconstituted): Store at -20°C for long-term stability (up to 24 months) or at 2–8°C for shorter periods, protected from light and moisture. Avoid repeated freeze-thaw cycles.

Reconstituted: Store at 2–8°C and use within 4–6 weeks. For longer storage, aliquot into single-use volumes and freeze at -20°C to avoid degradation from repeated freeze-thaw cycles. See our full peptide storage guide.

Safety Profile in Research

As with all research peptides, investigators should follow standard laboratory safety protocols, including appropriate personal protective equipment (PPE) when handling reconstituted solutions. IPP-2 TRZ 10mg is for in-vitro and laboratory research use only and is not intended for human consumption, therapeutic use, or diagnostic purposes. A downloadable Research Product Safety Sheet is available in the Documentation & Research Resources section on this page.

Frequently Asked Questions

What is IPP-2 TRZ 10mg used for in research?

IPP-2 TRZ 10mg is a dual GIP/GLP-1 receptor agonist used in laboratory research to study incretin-receptor signaling, pancreatic beta-cell physiology, energy homeostasis, and comparative metabolic pharmacology. It is intended strictly for research use.

How does IPP-2 TRZ differ from IPP-1 SM?

IPP-1 SM is a GLP-1 receptor monoagonist, whereas IPP-2 TRZ engages both the GIP and GLP-1 receptors as a single molecule. Researchers use the two side by side to characterize how dual-receptor engagement alters signaling relative to GLP-1 activation alone.

What is the purity of IPP-2 TRZ 10mg?

Each batch is verified at ≥99% purity by HPLC and mass spectrometry, with quality-assurance documentation confirming identity and composition.

How should IPP-2 TRZ 10mg be reconstituted?

Add bacteriostatic or sterile water to the lyophilized powder using a sterile syringe and swirl gently to dissolve. The volume added sets the working concentration. See our reconstitution guide for details.

Why Buy IPP-2 TRZ from Iron Peak Peptides?

Every batch of IPP-2 TRZ 10mg undergoes third-party analytical testing—HPLC, mass spectrometry, and endotoxin screening—to verify purity, identity, and composition, with batch-specific quality-assurance documentation included. Iron Peak Peptides maintains full traceability from raw material to finished vial, ships quickly with proper handling, and backs every order with responsive research-support. When you choose IronPeak, you partner with a supplier that prioritizes scientific rigor and product quality above all else.

References

1. Frías JP, Davies MJ, Rosenstock J, et al. IPP-2 TRZ versus IPP-1 SM Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. IPP-2 TRZ Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3-14.